C-CAR168 represents a novel bi-specific CAR-T therapy targeting both CD20 and BCMA, aimed at treating central nervous system autoimmune diseases that are refractory to standard therapies. The market for such therapies is expanding, particularly as existing treatments often fail to provide adequate relief for patients with conditions like Multiple Sclerosis (MS) and Neuromyelitis Optica Spectrum Disorders (NMOSD). The competitive landscape includes other CAR-T therapies and emerging biologics targeting similar pathways. Given the high unmet need in this patient population, successful outcomes could position C-CAR168 favorably in a niche but growing market. Diligence should focus on the safety profile and efficacy data emerging from this trial, as these will be critical for future investment and partnership opportunities.